Broda Tech News
The effectiveness of medication depends on the method of administration
Treatments can often be improved by finding optimal drug formulations or delivery systems.

 


March 14, 2017: New US Patent Granted for a Supramolecular Smart Drug Delivery Technology.

September 10, 2016: Broda Technologies Co., Ltd. today announced it has been granted Japanese Patent Registration No. 5980304 on August 5, 2016 for a patent titled “Reversely Thermal-Reversible Hydrogel Compositions”.

Febuary 23, 2016:Redwood Pharma raises SEK 6.6 million in private placement to fund development of its lead product candidate RP101 for the treatment of chronic Dry Eye Disease with Broda Technologies' IntelliGel® drug delivery system.

June 25, 2015: Broda Technologies entered a license agreement with Redwood Pharma AB of Sweden for its novel IntelliGel® drug delivery system - A smart supramolecular hydrogel drug delivery system for the development of new ophthalmic therapies.

March 21, 2015: Dr. Shao Xiang Lu and Dr. Letian Liu at Broda Tech have published an article entitled "Delivery of Smart, Functional Innovative Materials: A Supramolecular Chemistry Approach to Anti-Aging & Acne Products" on March issue of Euro Cosmetics Magazine.

October 21, 2014: Broda Receives US Patent for Thermal-Reversible Hydrogel Drug Delivery System - Advanced Supramolecular Drug Delivery Technology Platform for Water Insoluble or Sparely Soluble Drugs.

November 24, 2013: Broda Launches Advanced Broda™ Skincare Acne System that Will Reenergize OTC Acne Market - A highly effective patent-pending formula for acne treatment while providing skin care benefits for all skin types.

October 2, 2012: Dr. Shao Xiang Lu, President of Broda Technologies Co., Ltd., has been invited to talk at Innovation Prize Finalists which will be held as a part of Innovation Days 2012 Conference in Paris, France on October 2, 2012. The topic of his presentation is "IntelliGel™  ̶̶ ̶̶ ̶̶  Supramolecular Smart Hydrogel Drug Delivery System".

June 18, 2012: Broda IntelliGel™ project has been selected in the 15 finalists by The Universal Biotech Innovation Prize 2012. The Universal Biotech Innovation Prize is open to Small and Medium Enterprises from Europe and China and to academics researchers on: preventive and curative therapies, medical devices, and technology tools.

March 22, 2012: Broda Anti-fungal IntelliGel™ had received "Clinical Protocol Approval" and "Principle Investigator Approval" from US IRB.

July 26, 2011: Broda company's profile was published by Lux Research on innovative companies active in emerging technologies. For details, please visit: https://portal.luxresearchinc.com/research/profile_excerpt/Broda_Technologies.